Hemodynamic significance of periprocedural myocardial injury assessed with N-terminal pro-B-type natriuretic peptide after percutaneous coronary intervention in patients with stable and unstable coronary artery disease (from the JUMBO-TIMI 26 trial)

What Was Tested

The paper reports a study of BNP (Nesiritide), published as a randomized controlled trial.

The clinical relevance of periprocedural myocardial injury related to percutaneous coronary intervention (PCI) remains controversial.

The researchers measured the serum level of NT-pro-BNP using the Elecsys 2010 proBNP assay at baseline, 4 to 6 hours, and 12 to 24 hours in 747 patients undergoing elective or urgent PCI and enrolled in the JUMBO-TIMI 26 trial.

Who Took Part

According to the abstract, 24 patients were involved.

PubMed indexes the participants as teenagers, adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

In design terms this was a randomized study.

Because people in this BNP (Nesiritide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

What Was Measured

The researchers measured the serum level of NT-pro-BNP using the Elecsys 2010 proBNP assay at baseline, 4 to 6 hours, and 12 to 24 hours in 747 patients undergoing elective or urgent PCI and enrolled in the JUMBO-TIMI 26 trial.

PubMed files the paper under topics including Angina Pectoris, Angioplasty, Balloon, Coronary, Biomarkers, Incidence, Myocardial Infarction, Natriuretic Peptide, Brain and Peptide Fragments.

What This Means in Plain Language

The paper is a randomized study of BNP (Nesiritide) in 24 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2007 (The American journal of cardiology), a journal based in United States.

More context: the BNP (Nesiritide) compound page, all human trials.